No abstract

Oxaliplatin (L-OHP) is one of the effective chemotherapeutic drugs for colorectal cancer (CRC). Further investigation into the molecular mechanism of chemoresistance could improve outcomes for patients with colorectal cancer. Recently, microRNAs have been reported as a key in drug resistance of tumors. In this study, we aimed to investigate the effects of miR-153-5p in L-OHP-resistant CRC cells, and its underlying mechanism. Downregulation of miR-153-5p was observed in CRC cells, while upregulation of miR-153-5p enhances the chemosensitivity of CRC/L-OHP cells. The autophagy of CRC/L-OHP cells was markedly increased after exposure to L-OHP but abolished by the upregulation of miR-153-5p. Dual-luciferase reporter assays validated that Bcl-2 was a direct target of miR-153-5p. In conclusion, our data suggested that miR-153-5p was a mediator of cisplatin resistance in colorectal cancer by affecting Bcl-2-mediated autophagy, indicating a new therapeutic target for CRC treatment.

Lifestyle changes in modern society has led to higher consumption of high-fat and high-cholesterol foods. The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing, and the age of onset is reducing. Approximately 25%-45% of adults worldwide are affected by NAFLD (Bellentani et al., 2010); NAFLD has become the first liver disease to occur in developed countries. In China, it is the secondmost common liver disease after viral hepatitis and its incidence has been increasing continuously (Zhou et al., 2019). Therefore, efforts must be made to reduce the burden of NAFLD.NAFLD is characterized by abnormal lipid accumulation in hepatocytes (Boutari et al., 2018). Studies have revealed that being overweight, oxidative stress, and insulin resistance are the main causes of NAFLD (Gomaraschi et al., 2019;Rives et al., 2020). NAFLD can progressively develop into cirrhosis and subsequently into hepatocellular carcinoma. The incidence of cirrhosis in patients with NAFLD occurring within 10 years of onset is as high as 25% (Bhagat